Chiral Resolution and Serendipitous Fluorination Reaction for the Selective Dopamine D3 Receptor Antagonist BAK2-66.

@article{Kumar2014ChiralRA,
  title={Chiral Resolution and Serendipitous Fluorination Reaction for the Selective Dopamine D3 Receptor Antagonist BAK2-66.},
  author={Vivek Kumar and Ashwini K. Banala and Erick Garc{\'i}a and Jianjing Cao and Thomas M. Keck and Alessandro Bonifazi and Jeffery R. Deschamps and Amy Hauck Newman},
  journal={ACS medicinal chemistry letters},
  year={2014},
  volume={5 6},
  pages={
          647-51
        }
}
The improved chiral synthesis of the selective dopamine D3 receptor (D3R) antagonist (R)-N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)-3-hydroxybutyl)1H-indole-2-carboxamide (( R )-PG648) is described. The same chiral secondary alcohol intermediate was used to prepare the enantiomers of a 3-F-benzofuranyl analogue, BAK 2-66. The absolute configurations of the 3-F enantiomers were assigned from their X-ray crystal structures that confirmed retention of configuration during fluorination with N,N… 
View on PubMed
doi.org
12 Citations
Highly Influential Citations
1

Figures and Tables from this paper

12 Citations

Citation Type

Citation Type

Investigation of novel primary and secondary pharmacophores, and 3-substitution in the linking chain of a series of highly selective and bitopic dopamine D3 receptor antagonists and partial agonists.
TLDR
Off-target binding affinities, functional efficacies, and metabolic profiles revealed critical structural components for D3R selectivity as well as drug-like features required for development as pharmacotherapeutics.
The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D3 Receptor (D3R) Selective Agonists.
TLDR
Inspired by the potential for chemical modification of the D3 preferential agonists (+)-PD128,907 and PF592,379, this work synthesized bitopic structures to further improve their D3R selectivity and found that the (2 S,5 S) conformation of scaffold 2 resulted in a privileged architecture with increased affinity and selectivity for the D2R.
Structural Basis and Mechanism of Chiral Benzedrine Molecules Interacting With Third Dopamine Receptor.
TLDR
The results suggest that the D3 R protein can recognize chiral benzedrine molecules and influence their different addictive and pharmacological effects in biochemical systems.
Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R).
TLDR
This work synthesized a series of molecules in which the primary and secondary pharmacophores were derived from the D3R-selective antagonists SB269,652 and SB277011A, whose structural similarity and pharmacological disparity provided the perfect templates for SAR investigation.
Discovery, Optimization and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist.
TLDR
Results suggest that ML417 is a novel and uniquely selective D3R agonist that may serve as both a research tool and a therapeutic lead for the treatment of neuropsychiatric disorders.
An approach to (4-fluoroalkyl-1-alkyl-1H-pyrazol-3-yl)methylamines
Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment.
TLDR
Findings support the D3R as a target for opioid dependence treatment and compound 19 as a new lead molecule for development.
2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-protein Coupled Receptors - The Whole is Greater Than the Sum of its Parts.
TLDR
The genesis of designing bivalent or bitopic molecules that engender unique pharmacological properties began with Portoghese's work directed toward opioid receptors, and it is critical to note the synergistic relationship among all three of these components as they contribute to the overall interaction of these molecules with their receptor proteins.
High Affinity Dopamine D3 Receptor (D3R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D3R Knockout Mice
TLDR
A series of D3R-selective 4-phenylpiperazines with improved metabolic stability and off-target binding at selected 5-HT receptor subtypes are reported, including compounds 16 and the classic D 3R antagonist SB277011A, which were effective in reducing self-administration of heroin in wild-type but not D2R knockout mice.
Targeting the dopamine D3 receptor: an overview of drug design strategies
TLDR
This review summarizes the functional and pharmacological characteristics of D3Rs, including the design and clinical relevance of full agonists, partial agonists and antagonists, as well as the capacity of these receptors to form active homodimer, heterodimers or higher order receptor complexes as pharmacological targets in several neurological and neurodegenerative disorders.
...
1
2
...

References

SHOWING 1-10 OF 23 REFERENCES
N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity.
TLDR
A pivotal role is supported for the D3R E2 loop and the carbonyl group in the 4-phenylpiperazine class of compounds and a point of separation between structure-activity relationships at D3 R and D2R is revealed.
N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists.
TLDR
Some of the most D3-selective compounds reported to date that show high affinity for D3 and approximately 400-fold selectivity over the D2 receptor subtype are discovered, further underscoring their value as in vivo research tools.
Dopamine D2, D3, and D4 selective phenylpiperazines as molecular probes to explore the origins of subtype specific receptor binding.
TLDR
These chemically similar but biologically divergent target compounds served as molecular probes for radioligand displacement experiments, mutagenesis, and docking studies on homology models based on the recent crystal structure of the beta2-adrenergic receptor.
Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype.
TLDR
In an attempt to design a novel class of D3 ligands with which to study this receptor system, a series of chemically divergent compounds that possessed various structural features that exist within several classes of reputed D3 agents was screened and compared to the recently reported NGB 2904.
A Single Glycine in Extracellular Loop 1 Is the Critical Determinant for Pharmacological Specificity of Dopamine D2 and D3 Receptors
TLDR
It is demonstrated that the 4-phenylpiperazine moiety in this class of D3R-selective compounds binds to the conserved orthosteric binding site, whereas the extended aryl amide moiety is oriented toward a divergent secondary binding pocket (SBP).
Molecular determinants of selectivity and efficacy at the dopamine D3 receptor.
TLDR
Structural features of the receptor that are critical to selectivity and efficacy can be used to design highly D3R-selective ligands with targeted efficacies and are generalizable to other GPCRs in which the SBP can be targeted by bitopic or allosteric ligands.
Unanticipated retention of configuration in the DAST fluorination of deoxy-4′-thiopyrimidine nucleosides with “up” hydroxyl groups
Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design.
Higher Binding of the Dopamine D3 Receptor-Preferring Ligand [11C]-(+)-Propyl-Hexahydro-Naphtho-Oxazin in Methamphetamine Polydrug Users: A Positron Emission Tomography Study
TLDR
It is concluded that the dopamine D3 receptor, unlike the D2 receptor, might be upregulated in brains of MA polydrug users, although lower dopamine levels in MA users could have contributed to the finding.
Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist
TLDR
The crystal structure of the human dopamine D3 receptor in complex with the small molecule D2R/D3R-specific antagonist eticlopride reveals important features of the ligand binding pocket and extracellular loops.
...
1
2
3
...